Awareness about Rabies Post Exposure Prophylaxis in Pakistan Among Patients and Health Care Workers: Results from an Asian Rabies Expert Bureau Study.
Summary of "Awareness about Rabies Post Exposure Prophylaxis in Pakistan Among Patients and Health Care Workers: Results from an Asian Rabies Expert Bureau Study."
Objective: To identify the gaps in information on rabies and post exposure prophylaxis (PEP) in relation to categorization of wound severity, wound washing and appropriate use of vaccine and rabies immunoglobulin after exposure, and define actions that should be taken at dog bite management centres for prevention of rabies occurring after animal bites. Study Design: Cross-sectional survey. Place and Duration of Study: A multicentre study across Pakistan conducted from 1st July 2007 to 31st January 2008. Methodology: A pre-tested questionnaire was distributed to the respective medical officers in 6 dog bite management centres across Pakistan from 1st July 2007 to 31st January 2008. Information was obtained about demographics of dog bite victims, the timing and type of PEP administered and their responses to the injury. Results: Out of 519 completed questionnaires the mean age of dog bite victims was 24 years. Over one-third were less than 18 years of age; male/female ratio was 4.9:1; 43% lived in rural Pakistan; 67.8% were classified as lower socioeconomic class; 98% animal bites were from dogs, of which 92.5% were first time bites. 45.5% wounds were classified as Category I (no risk), 42.7%, Category II (moderate risk) and 11.9% Category III (severe risk). Tissue culture vaccine (TCV) was used 54% by intramuscular route and 45% by intradermal route. Only 118 (22.9%) patients received rabies immunoglobulin (RIG). Critical analysis of the results reveals serious gaps in understanding of wound severity classification and correct application of PEP with vaccine and RIG. Conclusion: There is a dire need for improved awareness and understanding of dog bite management among health care givers in order to prevent rabies deaths.
Division of Infectious Diseases, The Indus Hospital, Karachi.
This article was published in the following journal.
Name: Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
- PubMed Source: http://www.ncbi.nlm.nih.gov/pubmed/21798137
- DOI: http://dx.doi.org/08.2011/JCPSP.491494
Medical and Biotech [MESH] Definitions
Vaccines or candidate vaccines used to prevent and treat RABIES. The inactivated virus vaccine is used for preexposure immunization to persons at high risk of exposure, and in conjunction with rabies immunoglobulin, for postexposure prophylaxis.
The prevention of infection or disease following exposure to a pathogen. This is most frequently addressed by administering a vaccine or anti-viral medication following exposure to a virus.
A genus of the family RHABDOVIRIDAE that includes RABIES VIRUS and other rabies-like viruses.
The type species of LYSSAVIRUS causing rabies in humans and other animals. Transmission is mostly by animal bites through saliva. The virus is neurotropic multiplying in neurons and myotubes of vertebrates.
An individual's objective and insightful awareness of the feelings and behavior of another person. It should be distinguished from sympathy, which is usually nonobjective and noncritical. It includes caring, which is the demonstration of an awareness of and a concern for the good of others. (From Bioethics Thesaurus, 1992)
To investigate rabies in Massachusetts, we analyzed bat rabies test results before and after introduction of raccoon variant rabies and after release of revised 1999 US Advisory Committee on Immunizat...
The socioeconomic status of the patients is the important factor for post-exposure prophylaxis (PEP). However, few investigations were designed to study the correlation between the socioeconomic statu...
The aim of this study was to understand the use and distribution of human rabies post exposure prophylaxis (PEP) vaccine in Bhutan and to identify risk factors for receiving an incomplete course of th...
A serum-free, purified vero cell rabies vaccine is safe and as immunogenic as the reference vaccine Verorab™ for pre-exposure use in healthy adults: Results from a randomized controlled phase-II trial.
Verorab™ was licensed in 1985 for both pre- and post-exposure prophylaxis of rabies. The next generation purified Vero cell rabies vaccine (PVRV-NG) is a highly purified vaccine. We performed a phas...
Unlike any other human infection, encephalitis caused by dog rabies virus is always fatal. Rabies and other lyssaviruses have been found in unexpected places, and human disease, especially paralytic r...
Evaluate the immunogenicity and safety of rabies vaccine given in a post-exposure prophylaxis regimen to healthy children and adults aged 10-60 years.
- To demonstrate that rabies vaccine administered according to the Thai Red Cross, (TRC)-ID regimen (2-2-2-0-1-1) is not inferior to rabies vaccine administered according to the...
A comparative,randomized (1:1)study to evaluate the safety and immunogenicity of a new chromatographically purified vero cell rabies vaccine (SPEEDA) and chromatographically purified vero...
Background. The World Health Organization recommends pre-exposure vaccination (PreP) to protect children living in canine rabies endemic countries. Including PreP in national childhood imm...
Rabies immune globulin is a product that is lifesaving to unvaccinated individuals exposed to the rabies virus. Rabies immune globulin is made from plasma from immune donors. Currently the...